Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Closes $30M Stock Offering

Premium

Tekmira Pharmaceuticals this week announced that it has completed the public offering of $30 million of its common stock.

Through the transaction, Tekmira sold 3.75 million shares at $8 apiece. The underwriters of the offering have a 30-day option to purchase an additional 15 percent of the shares to cover over-allotments.

Tekmira stock was selling for around $8.68 during midday trading on Wednesday.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.